I
n-stent restenosis (ISR) is a major limitation of coronary bare metal stent implantation. While investigational work in the field has mainly focused on the formation as well as putative predictors of ISR, little is known about the simultaneous progression of primarily untreated plaques in the coronary tree within the same patient. Without any interventional therapy, progression has been reported to occur in 7-20% of coronary plaques per year. Also, plaque progression apparently increases with severity of coronary artery disease as well as with patient anginal status. 1 In the present prospective study, we evaluated a patient cohort undergoing coronary stent implantation and six month re-angiogram to test whether progression in primarily untreated plaques would occur more frequently with target lesion ISR.
METHODS
In a prospective observational single centre registry, symptomatic patients undergoing first successful single stent implantation were enrolled between May 2001 and April 2002 at the Department of Cardiology, University of Bonn, Germany. Exclusion criteria were: angioplasty without stenting; presence of restenosis in the initial angiogram or previous coronary artery bypass grafting; multiple stent implantation in one lesion, or stenting in more than one lesion; significant left main coronary artery lesion; three vessel disease or chronic total occlusions; infection or inflammatory disease; and lack of angiographic follow up. Of 274 patients with first single stent implantation in native coronary lesions, control angiograms were done in 219 patients (80% of the eligible patients) at . 3 months and , 9 months, mean time 6 (1) months. In all patients, serum was collected before stent implantation, and C reactive protein (CRP) concentrations were measured using a commercially available kit (N High Sensitivity CRP, Dade Behring, Marburg, Germany).
Coronary angiograms were analysed by two independent observers and were evaluated with the Coronary Angiography Analysis System (CAAS II for Windows QCA V4.1, Pie Medical Imaging BV, Maastricht, The Netherlands). Baseline stenoses of . 20%, as compared to the proximal reference segment, were assessed for progression/regression, defined as . 20% increase/decrease in diameter stenosis. Any novel localised narrowing of . 30% at follow up was regarded as development of a de novo lesion. ISR was defined as . 50% diameter stenosis at follow up. Categorical variables were assessed by x 2 analysis. Normally distributed continuous data are presented as mean (SD). For univariate analyses comparisons between groups were made using the unpaired Student t test; probability values of p , 0.05 were considered significant.
RESULTS
Serial quantitative coronary analysis was completed in 219 patients treated by stent implantation for symptomatic coronary artery disease. A total of 219 stented segments and 134 untreated plaques were evaluated at the time of stent deployment and at follow up angiogram after 6 (1) months.
ISR was found in 61 of 219 (28%) target lesions. The ISR and non-ISR subgroups did not differ with respect to clinical variables such as age, sex, and medication (table 1). Only diabetes mellitus was more prevalent with ISR (p , 0.001), while other demographic and patient characteristics were comparable within both groups. Notably, pre-procedural CRP concentrations were substantially increased (p = 0.02) in patients with subsequent ISR (11.0 (16.0) mg/l v 5.6 (11.6) mg/l). Also, ISR development was associated with length of target lesion (p = 0.02), while other angiographic and procedural variables did not significantly differ between groups.
A angiographically normal segment, or plaque regression, were not found. As a key finding, 12 of a total of 15 (80%) progressive coronary plaques were associated with ISR of the initially treated target lesion, whereas only three plaques showed angiographic progression without concomitant ISR (fig 1; p , 0.001). Statistical evaluation revealed smoking (p = 0.02), but no other demographic, angiographic, or procedural variable, associated with progression of untreated plaques (table 1) . Baseline CRP concentrations in patients with later coronary progression were significantly increased (18.3 (17.9) mg/l v 6.9 (13.1) mg/l; p = 0.01).
DISCUSSION
We report on the progression of atherosclerosis in untreated coronary plaques in context with ISR development in a group of patients admitted to a single centre. We have shown that plaque progression after six months occurred in 11% of preexisting lesions beyond an ISR rate of 28%. As the central finding, lesion progression was highly (80%) present with concomitant ISR formation of the target lesion within the same patient. Recent observations had shown 7-12% progression per year for mild to moderate lesions that were associated with stable angina and conventional medical treatment. Patients with severe coronary artery disease that underwent re-angiography at eight months revealed a progression rate of 11% with stable angina and 15% with unstable angina. 1 Therefore, coronary plaque progression, as observed in the present study, reveals a maximum extent compared to previous findings, indicating a particularly severe and/or active atherosclerosis type present in our patient cohort.
These findings initiate the question for common systemic pathogenic factors that may influence both the treated target lesion and untreated, but diseased coronary plaques. Indeed, our data show elevated pre-procedural CRP concentrations predict ISR and, within the same patients, coincide with the progression of native coronary atherosclerosis. Since CRP exerts chemotactic effects on monocytes and macrophages, 2 increased leucocyte trafficking post-stent implantation 3 may include not only circulating monocytes 3 but also bone marrow derived progenitor cells, that have consistently been found in restenoses. 4 5 In conclusion, progression of primarily untreated coronary plaques is strongly associated with target lesion ISR formation. High baseline CRP concentrations may identify patients at risk for both the development of ISR and the progression of coronary atherosclerosis. 
